According to recent clinical practice guidelines from the American College of Physicians ACP , patients with subacute or chronic lower back pain should first - try nonpharmacologic treatments, such as superficial heat, massage, acupunc ture, or spinal manipulation.
If these fail to adequately relive pain symptoms, clinicians and patients then should consider pharmacologic treatment with nonsteroidal anti-inflammatory drugs NSAIDs as first-line therapy. Opioids should be reserved for patients who have first failed nonpharmacologic and nonopioid treatment strategies because they are associated with substantial harms and risk of abuse. Additionally, because NSAIDs are associated with gastrointestinal and renal risks, the pharmacist should recommend that the prescriber use the lowest effective NSAID dose for the shortest period of time necessary.
HC appears to be implementing nonpharmacologic treatment tai chi. Risk Summary: A clear association of drug use and birth defects, miscarriage, or adverse maternal or fetal outcomes has not been shown with human use; animal studies have demonstrated adverse events at clinically relevant doses. Animal studies using the IV formulation have not been performed. In humans, this drug and its metabolites cross the placental barrier. Large cohort studies have not found an association between maternal use in the first trimester and either adverse pregnancy outcomes or congenital malformations.
Some evidence of increased risk of neurodevelopmental disorders e. However, extrapolating causation from pharmaco-epidemiological studies to humans is tricky considering various confounders and biases inherent in the study design.
Associations seen in clinical cohort studies need clarification with randomized clinical trials RCTs , which would be difficult to perform ethically in pregnant populations. It is important to factor in the risk of untreated febrile illness in mother and child when evaluating risks and benefits of using this drug. In , the US Food and Drug Administration released results of their evaluation on published research studies looking at mothers who took this drug as either an over the counter or prescription product at any time during their pregnancy and the risk of attention deficit hyperactivity ADHD in their babies.
They found all studies reviewed had potential limitations in their designs that prevented drawing reliable conclusions. In a prospective birth cohort study Avon Longitudinal Study or Parents and Children [ALSPAC] maternal drug exposure was assessed by questionnaire at 18 and 32 weeks, children were assessed at 61 months. Mothers were questioned about behavioral problems in their children at 7 years old; children's behavioral problems were assessed using the Strengths and Difficulties Questionnaire SDQ.
A number of confounders were evaluated although a limitation of the study was lack of information for drug use. The authors suggest there may be an association between drug use during pregnancy and behavioral problems in childhood that may be due to an intrauterine mechanism. Further studies are needed to test alternatives to a causal explanation.
According to published animal studies, this drug may cause reduced fertility in both males and females described as decreased testicular weights, reduced spermatogenesis, reduced fertility; and reduced implantation sites, respectively. AU TGA pregnancy category A: Drugs which have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the fetus having been observed.
This drug should be used during pregnancy only if clearly needed. Embryofetal development in rats and rabbits given approximately 3 and 15 times, respectively, the maximum recommended human dose MRHD was not adversely effected. Dams receiving this drug at doses 3 times or more the MRHD during pregnancy and lactation, had pups with decreased body weight and survival.
There are no adequate and controlled studies in pregnant women. US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women. Use is not recommended and a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Comments: Infants exposed to this drug through breast milk should be closely monitored for excess sedation and respiratory depression; withdrawal symptoms can occur when maternal administration of hydrocodone is stopped or breastfeeding is stopped.
Maternal use of oral narcotics during breastfeeding can cause infant drowsiness, central nervous system depression, and even death. Newborns are particularly sensitive. Once a mother's milk comes in, it is best to provide pain control with a nonnarcotic analgesic. There are no studies describing drug levels of extended-release hydrocodone or its metabolites in breast milk.
Hydrocodone is metabolized to 6 active metabolites including hydromorphone. A decision should be made to discontinue breast-feeding or discontinue this drug, considering the importance of the drug to the mother. Excreted into human milk: Yes acetaminophen Yes hydrocodone Comments: -Breastfed infants should be monitored for excess sedation and respiratory depression; immediate medical attention should be sought if infant develops breathing difficulties or limpness.
Breastfed infants of mothers who receive opioids, especially newborns, can experience drowsiness and CNS depression, even death. A study in 30 breastfeeding women found mean and median hydrocodone infant daily doses of 3. Mean and median hydromorphone daily doses of 2. Of interest was that 2 women excreted much more hydromorphone than others which might represent ultrarapid CYP 2D6 metabolizers.
Caution is recommended. Excreted into human milk: Yes Comments; -This drug has been used without apparent harmful effects. This drug is excreted into breast milk in very small amounts. Published reports reveal peak levels occur 1 to 2 hours after dosing and are undetectable after 12 hours. Reports have also shown infants ingesting 90 mL of breast milk every 3 hours would receive an average of 0.
Other studies have shown similar calculated maximal maternal weight adjusted doses 1. If your dose is different, do not change it unless your doctor tells you to do so. The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses. Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing. It is very important that your doctor check your progress at regular visits.
This will allow your doctor to see if the medicine is working properly and to decide if you should continue to take it. If your condition does not improve within 2 or 3 weeks, or if it becomes worse, check with your doctor. Check with your doctor right away if you have anxiety, restlessness, a fast heartbeat, fever, sweating, muscle spasms, twitching, nausea, vomiting, diarrhea, or see or hear things that are not there.
These may be symptoms of a serious condition called serotonin syndrome. Your risk may be higher if you also take certain other medicines that affect serotonin levels in your body. This medicine will add to the effects of alcohol and other CNS depressants medicines that slow down the nervous system, possibly causing drowsiness.
Some examples of CNS depressants are antihistamines or medicine for hay fever, other allergies, or colds, sedatives, tranquilizers, or sleeping medicine, prescription pain medicine or narcotics, medicine for seizures or barbiturates, other muscle relaxants, or anesthetics, including some dental anesthetics.
Check with your doctor before taking any of the above while you are using this medicine. This medicine may cause some people to have blurred vision or to become drowsy, dizzy, or less alert than they are normally.
Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are dizzy or are not alert and able to see well. Cyclobenzaprine may cause dryness of the mouth. For temporary relief, use sugarless candy or gum, melt bits of ice in your mouth, or use a saliva substitute.
However, if your mouth continues to feel dry for more than 2 weeks, check with your medical doctor or dentist. Continuing dryness of the mouth may increase the chance of dental disease, including tooth decay, gum disease, and fungus infections. Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
0コメント